Intranasal Immunization with Chitosan/pCAGGS-<i>fla</i>A Nanoparticles Inhibits<i>Campylobacter jejuni</i>in a White Leghorn Model

Huang, Jinlin; Yin, Yanxin; Pan, Zhiming; Gong, Zhiyong; Zhu, Aiping; Liu, Xiufan; Jiao, Xinan

doi:10.1155/2010/589476

Cited by 45 publications

(26 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chitosan has shown promising results in i.n. split virus vaccines in mice (Bacon et al 2000), split virus and protein vaccines in humans (Read et al 2005;Sui, Chen, Fang, et al 2010;Sui, Chen, Wu, et al 2010) and split virus and DNA vaccines in poultry (Tischer et al 2002;Worrall et al 2009;Huang et al 2010;Rauw et al 2010). However, in our study vaccination with chitosan-adjuvanted inactivated AIV and TMC inactivated AIV particles did not induce AIV-specific serum Ig (de Geus et al 2011).…”

Section: 2contrasting

confidence: 48%

Induction of respiratory immune responses in the chicken; implications for development of mucosal avian influenza virus vaccines

Geus

Rebel

Vervelde

2012

Veterinary Quarterly

View full text Add to dashboard Cite

The risk and the size of an outbreak of avian influenza virus (AIV) could be restricted by vaccination of poultry. A vaccine used for rapid intervention during an AIV outbreak should be safe, highly effective after a single administration and suitable for mass application. In the case of AIV, aerosol vaccination using live virus is not desirable because of its zoonotic potential and because of the risk for virus reassortment. The rational design of novel mucosal-inactivated vaccines against AIV requires a comprehensive knowledge of the structure and function of the lung-associated immune system in birds in order to target vaccines appropriately and to design efficient mucosal adjuvants. This review addresses our current understanding of the induction of respiratory immune responses in the chicken. Furthermore, possible mucosal vaccination strategies for AIV are highlighted.

show abstract

Section: 2contrasting

confidence: 48%

Induction of respiratory immune responses in the chicken; implications for development of mucosal avian influenza virus vaccines

Geus

Rebel

Vervelde

2012

Veterinary Quarterly

View full text Add to dashboard Cite

show abstract

“…Studies have shown induction of an immune response toward Campylobacter flagellin, but this was not correlated with a decrease in colonization of the chicken gut (Khoury and Meinersmann, 1995; Widders et al, 1998; Huang et al, 2010; Meunier et al, 2016b). …”

Section: Campylobacter Vaccines For Poultry and Humansmentioning

confidence: 97%

Current and Potential Treatments for Reducing Campylobacter Colonization in Animal Hosts and Disease in Humans

2017

View full text Add to dashboard Cite

Campylobacter jejuni is the leading cause of bacteria-derived gastroenteritis worldwide. In the developed world, Campylobacter is usually acquired by consuming under-cooked poultry, while in the developing world it is often obtained through drinking contaminated water. Once consumed, the bacteria adhere to the intestinal epithelium or mucus layer, causing toxin-mediated inhibition of fluid reabsorption from the intestine and invasion-induced inflammation and diarrhea. Traditionally, severe or prolonged cases of campylobacteriosis have been treated with antibiotics; however, overuse of these antibiotics has led to the emergence of antibiotic-resistant strains. As the incidence of antibiotic resistance, emergence of post-infectious diseases, and economic burden associated with Campylobacter increases, it is becoming urgent that novel treatments are developed to reduce Campylobacter numbers in commercial poultry and campylobacteriosis in humans. The purpose of this review is to provide the current status of present and proposed treatments to combat Campylobacter infection in humans and colonization in animal reservoirs. These treatments include anti-Campylobacter compounds, probiotics, bacteriophage, vaccines, and anti-Campylobacter bacteriocins, all of which may be successful at reducing the incidence of campylobacteriosis in humans and/or colonization loads in poultry. In addition to reviewing treatments, we will also address several proposed targets that may be used in future development of novel anti-Campylobacter treatments.

show abstract

“…In an in vivo study, chitosan-DNA nanoparticles that carried the recombinant plasmid pCAGGS-flaA for the flaA gene encoding the major structural protein FlaA of Campylobacter jejuni induced effective immune response and might be a promising vaccine candidate against C. jejuni infection [76]. In addition, a chitosan solution containing the cross-reacting material (CRM 197 ) of diphtheria toxin induces high levels of antigen-specific IgG, secretory IgA, toxin-neutralizing antibodies and T cell responses, enhancing the immunization against Corynebacterium diphtheria [77].…”

Section: Nasal Administrationmentioning

confidence: 99%

Chitosan Formulations as Carriers for Therapeutic Proteins

Andrade

Antunes²,

Nascimento³

et al. 2011

CDDT

View full text Add to dashboard Cite

Protein drugs represent a significant part of the new pharmaceuticals coming on the market every year and are now widely spread in therapy to treat or relief symptomatology related to many metabolic and oncologic diseases. The delivery of therapeutic proteins is still a major drawback against their maximum pharmacodynamic due to their physicochemical properties, poor stability, permeability and biodistribution. Despite the fact that the parenteral route remains the primary route of protein administration, research continues on non-parenteral delivery routes. However, the high molecular weight of proteins, combined with their hydrophilic and charged nature, renders transport through membranes very difficult. In this regard, the biopolymer chitosan exhibits several favorable biological properties, such as biocompatibility, biodegradability, low-toxicity and mucoadhesiveness, which made it a promising candidate for the formulation of protein drugs. The success of a protein formulation depends not only on the stability of the delivery system but also on their ability to maintain the native structure and activity of the protein during preparation and the delivery, as well as during longterm storage of the formulation. Chitosan-based delivery systems have been proposed as valid approaches to provide such protective conditions. The development of novel protein delivery systems based on chitosan is a rising subject irrespective of the intended route of administration. In this review, the different approaches recently exploited to formulate and deliver therapeutic proteins are underlined.

show abstract

Intranasal Immunization with Chitosan/pCAGGS-flaA Nanoparticles InhibitsCampylobacter jejuniin a White Leghorn Model

Cited by 45 publications

References 26 publications

Induction of respiratory immune responses in the chicken; implications for development of mucosal avian influenza virus vaccines

Induction of respiratory immune responses in the chicken; implications for development of mucosal avian influenza virus vaccines

Current and Potential Treatments for Reducing Campylobacter Colonization in Animal Hosts and Disease in Humans

Chitosan Formulations as Carriers for Therapeutic Proteins

Contact Info

Product

Resources

About